Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$461.12 USD
+6.11 (1.34%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $459.58 -1.54 (-0.33%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$461.12 USD
+6.11 (1.34%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $459.58 -1.54 (-0.33%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
Zacks News
The Zacks Analyst Blog Highlights: Activision, Marriott, Intuitive Surgical, Edison International and TELUS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Activision, Marriott, Intuitive Surgical, Edison International and TELUS
Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025
by Zacks Equity Research
Weight Watchers' (WTW) plan to issue senior notes will aid the company in reducing cost of capital.
Top Stock Reports for Activision, Marriott & Intuitive Surgical
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Activision (ATVI), Marriott (MAR) and Intuitive Surgical (ISRG).
Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.
Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise
by Zacks Equity Research
Bruker's (BRKR) recent acquisition of Germany-based MERLIN buoys optimism for its growth within MALDI Biotyper business.
AmerisourceBergen (ABC) Rewards Investors With Dividend Hike
by Zacks Equity Research
AmerisourceBergen's (ABC) dividend hike adheres to the company's policy of rewarding stakeholders at regular intervals.
OPKO Health (OPK) Posts Wider-Than-Estimated Loss in Q3
by Zacks Equity Research
OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
Inogen Claims Top Position in Deloitte List on Solid Growth
by Zacks Equity Research
Inogen's (INGN) unique direct-to-customer business model has lent it a leading position in the United States.
QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.
TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y
by Zacks Equity Research
TransEnterix's (TRXC) reports unimpressive Q3 results, thanks to the constriction of deferred service revenues.
Dull MFA & Mineral Nutrition Sales Hurt Phirbo, Rivalry Rife
by Zacks Equity Research
Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.
Hologic (HOLX) Q4 Earnings & Revenues Top, Margins Down
by Zacks Equity Research
Solid double-digit growth at Hologic's (HOLX) molecular diagnostics and international business drives the top line in Q4.
Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag
by Zacks Equity Research
Genomic Health (GHDX) gains from strong adoption of its Oncotype DX test in Q3.
Hill-Rom (HRC) Banks on Product Launches, Competition Rife
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging.
Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.
Globus Medical (GMED) Q3 Earnings In Line, View Reiterated
by Zacks Equity Research
Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.
Baxter Posts Solid Q3, Broad Product Spectrum Raises Hopes
by Zacks Equity Research
Baxter's (BAX) convenient kidney dialysis solutions, regenerative tissue products, 3-in-1 oXIRIS set for continuous renal replacement therapy are the latest additions to the extensive product portfolio.
SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.
Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions help Haemonetics (HAE) deliver strong results in Q2.
VWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure
by Zacks Equity Research
VWR's third-quarter report impresses with growth in Americas and EMEA-APAC segments. The transaction with Avantor is also in process.
Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3
by Zacks Equity Research
Penumbra (PEN) witnesses strong growth across all geographical regions and product lines in Q3.
DaVita (DVA) Q3 Earnings Miss & Revenues Beat, '17 View Dull
by Zacks Equity Research
Strong growth in patient services is likely to boost DaVita's (DVA) growth trajectory in the coming quarters. DaVita's (DVA) continuous improvement in Kidney care is commendable as well.
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology (ALGN) consistently invests in R&D for product innovation.
Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.